Background-Drugs with I Kr -blocking action cause secondary long-QT syndrome. Several cases have been associated with mutations of genes coding cardiac ion channels, but their frequency among patients affected by drug-induced long-QT syndrome (dLQTS) and the resultant molecular effects remain unknown. Methods and Results-Genetic testing was carried out for long-QT syndrome-related genes in 20 subjects with dLQTS and 176 subjects with congenital long-QT syndrome (cLQTS); electrophysiological characteristics of dLQTS-associated mutations were analyzed using a heterologous expression system with Chinese hamster ovary cells together with a computer simulation model. showed complex gating defects without dominant negative effects or a relatively mild decreased current density. Drug sensitivity for mutant channels was similar to that of the wild-type channel. With the Luo-Rudy simulation model of action potentials, action potential durations of most mutant channels were between those of wild-type and cLQTS. Conclusions-dLQTS had a similar positive mutation rate compared with cLQTS, whereas the functional changes of these mutations identified in dLQTS were mild. When I Kr -blocking agents produce excessive QT prolongation (dLQTS), the underlying genetic background of the dLQTS subject should also be taken into consideration, as would be the case with cLQTS; dLQTS can be regarded as a latent form of long-QT syndrome. (Circ Arrhythmia Electrophysiol. 2009;2:511-523.)
interval and TdP. Sesti et al 4 demonstrated that a polymorphism of the KCNE2 gene (T8A) is present in 1.6% of the population and is associated with drug-induced TdP related to quinidine and to sulfamethoxazole/trimethoprim administration. We have also previously reported that a mutant SCN5A channel (L1825P), found in an elderly woman with cisaprideinduced TdP, appeared to have unique electrophysiological characteristics with both loss and gain of functions for the cardiac sodium current. 5 In addition, there have been several case reports with long-QT syndrome-associated gene mutations in dLQTS. 6 -10 The accurate prevalence of long-QT syndrome-related gene mutations in a larger dLQTS cohort, however, remains unknown, and the relationship between genotypes and cellular electrophysiology has not been fully examined. The present study therefore aimed to survey mutations in long-QT syndrome-related genes responsible for dLQTS in 20 patients who had been referred to our institutes consecutively over the past 11 years and analyze the functional effects induced by these mutations.
Methods

Subjects
Blood samples of 305 subjects with long-QT syndrome, comprising 196 long-QT syndrome probands and 109 family members were referred to Kyoto University Graduate School of Medicine and Shiga University of Medical Sciences from March 1996 to January 2006 for genetic analysis. A diagnosis of dLQTS was made in those subjects who had not previously been diagnosed with long-QT syndrome and who only developed typical ECG features of QT prolongation after administration of culprit drugs. A diagnosis of cLQTS was made in those subjects with clinical phenotypes of long-QT syndrome, but without the involvement of secondary factors (eg, drugs, hypokalemia, or bradycardia). Among the subjects, 20 probands had drug-induced cardiac events (10.2% of long-QT syndrome probands). Their clinical information was collected, including family history of sudden death age 30 years or younger and long-QT syndrome members, previous syncope, ECGs, and serum electrolyte levels at the time of cardiac events. TdP was defined as either nonsustained or sustained ventricular tachycardia showing variation in the electronic polarity of the QRS complex and a "short-long-short" initiating sequence. 11 Written informed consent was obtained from all subjects in accordance with the guidelines approved by our institutional review board. QT intervals were measured in lead II or V 5 , using the Bazett formula, 12 before and after allowing sufficient time for the complete washout of drugs.
Schwartz scores 13 were calculated in all probands. A Schwartz score м4 points indicates that long-QT syndrome is definitely present, a score of 2 or 3 points indicates there is a strong possibility that long-QT syndrome is present, whereas a score Ϲ1 point indicates a low probability of long-QT syndrome, respectively. 13 
Mutation Analysis
The protocol for genetic analysis was approved by and performed under the guidelines of the Institutional Ethics Committee at Shiga University of Medical Science. Genomic DNA was isolated from peripheral white blood cells using conventional methods. Genetic screening was performed for KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, and KCNJ2, using polymerase chain reaction/single-strand conformational polymorphism (PCR-DHPLC, WAVE system, Transgenomic Inc, Omaha, Neb) analysis. 14, 15 For the abnormal DHPLC patterns, we determined the DNA sequences on both strands with an automated sequencer (PRISM 3130 Sequencer, Perkin Elmer, Calif). 
Expression Plasmids
Cell Transfection
Functional potassium channels were expressed transiently in Chinese hamster ovary (CHO) cells by transfecting the same amount of ␣ subunit plasmids (1 g/mL KCNQ1 cDNA or 2 g/mL KCNH2 cDNA). For the analysis of I Ks currents, the same amount of pIRES/CD8-KCNE1 was coexpressed. Cells were trypsinized, diluted with Dulbecco Modified Eagle's Medium (DMEM, Nacalai Tesque, Kyoto, Japan) supplemented with 10% fetal bovine serum, 30 U/mL penicillin, and 30 g/mL streptomycin. The DMEM used for cell culture dishes was changed to OptiMEM (Invitrogen, Carlsbad, Calif) for transfection, and, after the addition of 10 L lipofectamine (Invitrogen) and cDNA, the cells were incubated at 37°C for 3 hours, unless otherwise described. OptiMEM was then replaced by DMEM and the cells were subjected to electrophysiological measurements 48 to 72 hours after transfection. Cells expressing the potassium channels were selected through detection of green fluorescent protein and by decoration with anti-CD8 antibody-coated beads.
Electrophysiology
Whole-cell patch-clamp recordings were made at 37°C, using an EPC-8 patch-clamp amplifier (HEKA, Lambrecht, Germany) with pipettes filled with (in mM): 70 aspartate, 70 KOH, 40 KCl, 10 KH 2 PO 4 , 1 MgSO 4 , 3 Na 2 -ATP, 0.1 Li 2 -GTP, 5 HEPES, and 5 EGTA (pH 7.3 with 1N KOH), with a resistance of 2.0 to 4.0 mol/L⍀. The external superfusate contained (in mM): NaCl 140, KCl 5.4, MgCl 2 0.5, CaCl 2 1.8, NaH 2 PO 4 0.33, glucose 5.5, and HEPES 5 (pH 7.4 with NaOH). Data were filtered at 2 kHz. Data acquisition was performed using PatchMaster acquisition software (HEKA). The holding potential was set at Ϫ80 mV. Current densities (pA/pF) were calculated for each cell studied, by normalizing peak tail current amplitude to cell capacitance. Current-voltage relations were fitted with the Boltzmann function:
where V 1/2 indicates the potential at which the activation or inactivation is half-maximal, Vm the test potential, and k the slope factor. Drug sensitivities were examined by various concentrations for erythromycin, disopyramide, and pirmenol (gift from Pfizer Inc, Groton, Conn). Depolarizing pulses were applied every 15 seconds and peak tail currents at Ϫ60 mV after ϩ20 mV test potential were recorded in the absence or presence of various concentrations of agent. Percent inhibition was calculated by dividing the peak amplitude in the presence of drug by control. Drug concentration-inhibition relations were fitted to the Hill equation;
where IC 50 is the amount of drug necessary to produce the halfmaximal inhibition of I Kr tail currents, and n is the Hill coefficient for the fit.
Computer Simulation
The dynamic Luo-Rudy model (Clancy and Rudy 2001 model) of a ventricular cell was used, with recent modifications and action potentials were simulated using a previously reported model. 16 The ratio of I Kr and I Ks conductance of M cell layer was set at 23:7. Based on the experimental data of voltage-clamp recordings of KCNQ1 and KCNH2 channels heterologously expressed in CHO cells, we constructed Markov or Hodgkin-Huxley models for simulated mutant channels as compared with mutants associated with cLQTS (see supplemental data 1). To make the mutant channel models, we decreased the conductance of each channel as appropriate for the decreased current density and looked for adequate changes for mutant channels by changing each coefficient value, in turn, for gating states associated with impaired gating defects. The simulation for voltage-clamp experiments was calculated using the 4th-order Runge-Kutta method with a fixed-time step of 0.020 ms. The simulation programs (see supplemental data 1) were coded in Cϩϩ and implemented for personal computers.
Statistical Analysis
Experimental data are expressed as meanϮSE and other clinical data as meanϮSD, and the statistical comparisons were made using the unpaired Student t test. Differences in the positive mutation rate between 2 groups were analyzed by 2 and Fisher exact probability test. Statistical significance was considered as PϽ0.05. Table 1 ) a prolonged QT interval of over 480 ms was maintained after washout. The average R-R interval immediately before TdP was 1.2Ϯ0.4 seconds, and the average serum potassium level after TdP was 3.9Ϯ0.6 mEq/ mL. In the majority of subjects (nϭ14, 70%), dLQTS was induced by antiarrhythmic drugs (disopyramide, pirmenol, cibenzoline, procainamide, and aprindine in 8, 3, 1, 1, and 1 subjects, respectively; cases 1 to 14); the remaining cases were induced by antihistamines, antibiotics, psychiatric, or miscellaneous drugs (cases 15 to 20 in Table 1 ). None had a family history of long-QT syndrome, whereas 3 subjects (cases 4, 14, and 20) had unexplained syncope and another subject (case 17) had a family member with sudden cardiac death. During a mean follow-up period of 52Ϯ44 months after discontinuing drugs, 1 subject without any gene mutations (case 9) had recurrent ventricular fibrillation. Compared with cLQTS, the age at first cardiac event in subjects diagnosed with dLQTS was significantly older (dLQTS versus cLQTS; 65Ϯ16 versus 19Ϯ18 years, PϽ0.001). No subject in the dLQTS group had a family member with long-QT syndrome (dLQTS versus cLQTS; 0% versus 24% subjects, PϽ0.01). The QT c interval in dLQTS subjects was significantly shorter than in cLQTS subjects (dLQTS versus cLQTS; 446Ϯ29 versus 507Ϯ71 ms, PϽ0.001); the Schwartz score was significantly lower in dLQTS than in cLQTS (dLQTS versus cLQTS; 0.9Ϯ1.4 versus 4.1Ϯ2.1,
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PϽ0.001).
In 8 (40%) dLQTS subjects, the genetic analysis identified 8 mutations in LQTS-related genes; 2 KCNQ1, 5 KCNH2, and 1 SCN5A (Table 1) . These variants were not observed in the control subjects (220 chromosomes from non-cLQTS and non-dLQTS subjects), suggesting that they represented disease-related mutations. The 91 cLQTS patients also had gene mutations such as 33 KCNQ1, 36 KCNH2, 12 SCN5A, 2 KCNE2, and 8 compound mutations, and the positive mutation rate was similar between dLQTS and cLQTS subjects (8 of 20 [40%] versus 91 of 176 [52%] subjects, respectively, Pϭ0.32, Figure 1A ). These mutations were found in only 3 of 14 (21%) subjects with TdP induced by antiarrhythmic drugs. In contrast, 5 of 6 subjects with TdP induced by nonantiarrhythmic drugs had gene mutations (83%; versus patients with TdP induced by antiarrhythmic drugs, PϽ0.05) ( Figure 1B) . Seven of the 8 mutations were located in the nonpore regions (red circles in Figure 1C ), except for the A614V-KCNH2 mutation in a case of hydroxyzine-induced TdP. 17 The green circles in Figure 1C indicate the location of 8 mutations previously reported in dLQTS. [5] [6] [7] [8] [9] [10] 
Clinical Characteristics of Genotyped dLQTS Subjects
Detailed subject characteristics are presented in Table 1 and the supplemental data 2. Case 2 (M756V/KCNH2) was a 63-year-old man who was admitted with syncope after taking pirmenol (300 mg/d). Case 4 (H492Y/KCNH2) was a 52-year-old woman who had syncope while taking disopyramide (300 mg/d). She had previously had 1 episode of unexplained syncope. Case 14 (R243H/KCNQ1) was a 52-year-old woman who had repetitive syncope after taking aprindine (60 mg/d). Case 15 (S706F/KCNH2) was a 21-year-old woman who complained of sudden onset of palpitations and dyspnea after taking amphetamine and methamphetamine. An SCN5A mutation (L1825P/SCN5A) (case 16), has been reported previously 5 ; this concerned a 70-year-old woman who had TdP and prolongation of the QT interval after taking cisapride (5 mg/d) and pirmenol (200 mg/d). Case 17 (D342V/KCNH2) was a 70-year-old woman who had repetitive syncope due to erythromycin intake (1200 mg/d). This subject had a 24-yearold sister who had died suddenly, but it is not unknown if her sister had suffered from LQTS. Case 18 (R231C/KCNQ1) was a 72-year-old woman who had presyncope while taking probucol (250 mg/d). Case 20 concerned a 34-year-old woman (A614V/KCNH2 according to Table 1 ) who had syncope and QT prolongation induced by hydroxyzine (3 mg/d). 17 None of the 20 subjects in the study had structural heart disease or a family history of documented LQTS. In genotyped families, a genetic test for 5 members revealed 1 R243H/KCNQ1 mutation carrier. This carrier had no syncope and a normal QT interval (QT c , 400 ms). The Schwartz scores in the 8 subjects with mutations were 1.0Ϯ1.5 points (range, 0 to 4 points). Thus, among the genotyped dLQTS subjects in this current study, there was only a low or moderate possibility of LQTS being present, both before taking the drugs or after their withdrawal. 
Electrophysiological Characteristics of Mutations Associated With dLQTS
The biophysical effects of the respective KCNQ1 and KCNH2 mutations were analyzed using a heterologous expression system with the CHO cell line. The upper panel of Figure 2A shows representative current traces for WT and 2 mutant KCNQ1 channels; the lower panel shows those recorded from cells cotransfected with WT and each mutant. On their own, both mutants displayed smaller currents compared with WT, whereas the R231C channel was a slightly open K ϩ leak channel. Under heterozygous conditions, however, they displayed currents comparable to those of WT without dominant negative effects.
At the end of the depolarizing pulse to ϩ40 mV, current densities were smaller than those of WT channels (77.0Ϯ10.6 pA/pF) in R231C/WT (39.6Ϯ11.9 pA/pF, PϽ0.05 versus WT) but not in R243H/WT (61.9Ϯ10.7 pA/pF) ( Figure 2B ). On the other hand, the R243H channels showed a significant positive shift of steady-state activation curve ( Figure 2C ). Half activation voltages (V 1/2 ) and k were Ϫ8.2Ϯ3.1 mV and 12.6Ϯ0.6 for WT, Ϫ12.8Ϯ3.6 mV and 13.6Ϯ1.3 for R231C/ WT, 1.7Ϯ3.1 mV and 12.9Ϯ0.6 for R243H/WT, respectively (V 1/2 : WT versus R243H/WT, PϽ0.05). Figure 2D shows representative families of current traces (left panel) and time constants (right panel) of deactivation in each channel. The time course of deactivating kinetics could be fitted by a single-exponential function. The R243H/WT channel had faster deactivation process over Ϫ60 mV, whereas this process in the R231C/WT channel was slower than WT under Ϫ90 mV. Figure 3A shows representative families of current traces recorded during depolarizing pulses from CHO cells transfected with KCNH2 cDNAs as indicated in the graph. The left column depicts current traces from cells transfected with each construct alone and the right column those recorded under heterozygous conditions except for the uppermost traces (WT 1 g). When expressed alone, D342V was nonfunctional and 3 other mutations displayed functional channels. When coexpressed with WT, D342V showed weak dominant negative effects, whereas the other 3 channels showed nondominant negative effects. The functional outcome of the remaining mutation, A614V-KCNH2, 17 has recently been reported. Using an oocyte expression system, Nakajima et al 18 reported that the A614V channel showed loss of function in a dominant negative manner, and the results from the present study were almost identical (18% current density of WT).
Current densities at the end of a 2-second depolarization pulse were calculated in multiple cells and plotted as a function of test potential in Figure 3B . At the end of the depolarizing pulse to ϩ20 mV, the densities were smaller than those of WT channels (36.2Ϯ6.8 pA/pF) in D342V/WT (18.7Ϯ4.5 pA/pF, PϽ0.05 versus WT) and S706F/WT (21.9Ϯ2.7 pA/pF, Pϭ0.055 versus WT). Those in H492Y/WT and M756V/WT were also smaller than in the WT, but the difference did not reach statistical significance.
The mean peak amplitudes of tail currents at Ϫ60 mV on repolarization from various test potentials (2-second duration) plotted as a function of test potentials are displayed in Figure 3C . H492Y and M756V channels displayed amplitudes of peak tail currents similar to WT. For example, the peak tail current densities after a test pulse to ϩ20 mV were 66.2Ϯ10.5 pA/pF for WT, 62.1Ϯ13.0 pA/pF for H492Y/WT, and 58.4Ϯ7.7 pA/pF for M756V/WT. On the other hand, the Mutations associated with nondominant negative effects of KCNQ1 channels. A, Current traces reconstituted in CHO. Current amplitude was normalized by respective cell capacitance and was indicated as the current density. B, Current-voltage (I-V) relationships for amplitudes of steady-state currents at the end of 4-second depolarizing pulses. Currents were elicited by depolarizing pulses from a holding potential of Ϫ80 mV to test potential between Ϫ50 to ϩ50 mV (with a 10-mV step increment), followed by repolarization to Ϫ50 mV to monitor tail current amplitude. The voltage-clamp protocol is shown in the inset. Open circles, WT (1 g); filled squares, mutant (1 g); filled circles, WT (0.5 g) plus mutant (0.5 g); and dotted lines, WT (0.5 g). All data were recorded from 10 to 25 cells. C, Steady-state activation curves for WT and WT plus mutants. D, KCNQ1 mutants modify deactivation time curse. Left column presents the time course of deactivation for each channel. Each inset illustrates scale bars of 2-nA and 1-second times. To examine the deactivation time course, a conditioning pulse to ϩ40 mV for 4 seconds from a holding potential of Ϫ80 mV was followed by hyperpolarizing test pulses between Ϫ120 mV and Ϫ20 mV in 10-mV increments (inset in graph on right). Currents were not leak-subtracted. Deactivation time constants (tau) were measured by fitting deactivating currents during test pulses at each potential with a single exponential. *PϽ0.05 versus WT. current densities of D342V/WT (1.5Ϯ0.9 pA/pF, PϽ0.001 versus WT) and S706F/WT (38.9Ϯ7.3 pA/pF, PϽ0.05 versus WT) channels were significantly smaller than WT. D342V/WT channel displayed currents smaller than WT 1 g (indicated by dotted line), whereas S706F/WT currents were similar to WT 1 g in size. Thus, D342V channels had weakly dominant negative suppression effects on reconstituted I Kr -like currents, whereas S706F had no dominant negative suppression effect. To examine the voltage dependence for activation, Boltzmann function curves were fitted to the relationship between peak tail currents and test voltages under respective conditions and are represented by solid lines in Figure 3C . Half inactivation voltages (V 1/2 ) were Ϫ23.2Ϯ1.6 mV for WT, Ϫ19.8Ϯ3.0 mV for D342V/WT, Ϫ24.6Ϯ1.4 mV for H492Y/WT, Ϫ26.1Ϯ1.5 mV for S706F/ WT, and Ϫ19.8Ϯ1.7 mV for M756V/WT, respectively (Figure 3D) . Therefore, the mutations did not affect the voltagedependent activation of the reconstituted I Kr -like channel.
Whether the mutations affected the inactivation kinetics of KCNH2 channels was then assessed. Figure 4A shows the voltage dependence of availability of WT and mutant channels measured by a brief repolarization method (inset). With a 1-second depolarizing pulse, peak tail current amplitudes (arrow in the inset) after short preconditioning voltage pulses (5 ms) are plotted against the voltage of conditioning pulse. Mutant channels caused significant voltage shift of channel Figure 3 . KCNH2 mutations identified in drug-induced LQT subjects produced various levels of functional effects. A, Current traces of I Kr reconstituted in CHO cells. Expression of the respective clones, indicated above each graph, all displayed I Kr -like currents, except for D342V. Current amplitude was normalized by respective cell capacitance and was indicated as the current density. B, Currentvoltage (I-V) relationships for amplitudes of steady-state currents at the end of 2-second depolarizing pulses. Currents were elicited by depolarizing pulses from a holding potential of Ϫ80 mV to test potential between Ϫ60 to ϩ50 mV (with a 10-mV step increment), followed by repolarization to Ϫ60 mV to monitor tail current amplitude. The voltage-clamp protocol is shown in the inset. C, I-V relationships for amplitudes of peak tail currents measured at Ϫ60 mV. Open circles, WT (2 g); filled squares, mutant (2 g); filled circles, WT (1 g) plus mutant (1 g); and dotted lines, WT (1 g). All data were recorded from 10 to 25 cells. D, Voltage dependence of activation for each channel. The data were fitted to a Boltzmann function.
availability to the hyperpolarizing direction compared with WT (V 1/2 of Ϫ58.3Ϯ4.7 mV for WT, V 1/2 of Ϫ61.4Ϯ6.5 mV for D342V/WT, Ϫ77.8Ϯ4.7 mV for H492Y/WT, Ϫ70.1Ϯ3.2 mV for S706F/WT, and Ϫ71.1Ϯ4.6 mV for M756V/WT, respectively). The time course to recovery from or the development of the inactivation (recovery from inactivation at hyperpolarized potentials and development of inactivation at ϾϪ70 mV) was analyzed by double or triple pulse protocols. The time course of inactivating kinetics could be fitted by a single-exponential function. Time constants thus calculated were significantly smaller than WT and mutant channels over a wide range of voltage (between Ϫ50 and ϩ40 mV for D342V/WT and H492Y/WT; between Ϫ30 and ϩ20 mV for S706F/WT; between Ϫ40 and 0 mV for M756V/WT, Figure 4B ). These results demonstrate that drug-induced LQTS mutants have accelerated inactivation kinetics. Figure  4C shows representative families of current traces (left panel) and time constants (right panel) of deactivation in each channel. When the time course of deactivating kinetics was fitted by a double-exponential function, the S706F/WT channel slightly accelerated the deactivation process ( Figure 4C) .
Most of the drugs that induced LQTS in the study subjects have been known to block I Kr in a concentration-dependent manner, 8,17,19 -22 whereas I Kr channel with KCNH2 mutations may have different drug sensitivities compared with the WT channel. Figure 5 shows 3 sets of drug concentration-current inhibition relationships associated with KCNH2 mutations with respect to erythromycin (5A), disopyramide (5B), and pirmenol (5C). In each case of drug-induced LQTS, an electrophysiological assay of current inhibition by the respective culprit drug was performed, for example, hydroxyzine, 17 erythromycin, disopyramide, and pirmenol. IC 50 s were not significantly different between WT and the respective mutant channels, suggesting that a change in drug sensitivity was not involved in causing the drug-induced TdP in the study subjects. ms from a holding potential of Ϫ80 mV was followed by a hyperpolarizing pulse to Ϫ120 mV for 5 ms, and subsequent depolarizing test pulses between Ϫ50 and ϩ40 mV in 10 mV steps were applied. In addition, a conditioning pulse to ϩ40 mV for 750 ms was applied from a holding potential of Ϫ80 mV, followed by test pulses to various potentials between Ϫ130 and Ϫ60 mV in 10 mV increments. The inset illustrates the voltage protocol. Inactivation time constants were measured by fitting inactivating currents during test pulses at each potential with a single exponential function. C, The S706F/KCNH2 mutant channel slightly accelerates deactivation time course. Left column, time course of deactivation for each channel. To examine the deactivation time course, a conditioning pulse to ϩ40 mV for 1.6 seconds from a holding potential of Ϫ80 mV was followed by hyperpolarizing test pulses between Ϫ70 mV and Ϫ40 mV in 10-mV increments for 16 seconds (inset). Currents were not leak-subtracted. Each inset illustrates scale bars of 200-pA and 5-second times. Deactivation time constants (tau) were measured by fitting deactivating currents during test pulses at each potential with double exponentials. The slow components of tau for the S706F/WT channel were smaller than that of WT; *PϽ0.05.
Computer Simulation of Ventricular Action Potentials
To compare how the functional changes caused by mutants affect ventricular action potentials, a simulation study was conducted using the Luo-Rudy computer model that incorporated the Markov 16 or Hodgkin-Huxley 23 process gating for the mutant channels ( Figure 6A ). Table 2 shows parameters of simulation that have been changed to fit to experimental results. First, the I Kr or I Ks conductance was reduced to the level observed in the D342V/WT, A614V/WT, and R231C/WT channels. The deactivation time course for R231C/WT was also fitted by modifying a parameter. Second, the transition rate was changed accordingly from inactivation to open states (␣i) and fitted with the experimental data seen in H492Y/WT and M756V/WT channels. Acceleration of inactivation induced by modifying the transition rate ␣i reproduced smaller amplitudes for I-V relationships and negative shift of steady-state inactivation curve ( Figure 4A) ; these findings were compatible with the experimental results ( Figure 3, A through C) . Third, some parameters were altered to simulate the S706F/WT model, by reducing the I Kr conductance, modifying ␣i, and increasing the transition rate from open to deactivation states. This was followed by change to parameters associated with the activation and deactivation rates for the R243H/WT model. Finally, not only was I Na conductance decreased in the subjects, but the burst mode was also added to simulate the sustained current for the L1825P model. 24 The L1825P/WT channel was heterogeneously simulated to equally mix WT and L1825P models.
In the simulated M cells using the Luo-Rudy model, the order of increase in magnitude of action potential duration (APD) was A614V/WTϾR231C/WTϾD342V/WTϾS706S/ WTϾR243H/WTϭL1825P/WT ϾH492Y/WTϾM756V/WT for dLQTS mutations ( Figure 6B, middle panel) . Typically, for cLQTS mutations, the simulated APD was longer than for WT or drug-induced models, whereas APDs in drug-induced models were intermediate between those in WT and those in cLQTS (clinical information for simulated cLQTS are presented in supplemental Table 1 ).
Finally, an effort was made to reproduce action potentials in the presence of I Kr -blocking drugs ( Figure 6C ). Early afterdepolarizations appeared in all mutants where there were smaller reductions in the I Kr conductance compared with the corresponding WT. Because drug sensitivities for WT and mutant channels were not different ( Figure 5 ), the same inhibition rate was used in both the WT and mutant models and the I Kr conductance was gradually reduced at the cycle length of 1200 ms. As shown in Figure 6C , typically, when the I Kr conductance was theoretically decreased to 89% of the basal conductance for each channel, the D342V/WT model began to develop early afterdepolarizations, whereas the WT model produced only a 2.9% increase in APD.
Discussion
There were 3 major findings. 1 In 8 of 20 consecutive dLQTS subjects, 5 KCNH2, 2 KCNQ1, and 1 SCN5A heterozygous missense mutations were identified; there was a similar positive mutation rate with dLQTS compared with cLQTS. 2 Both KCNQ1 and KCNH2 mutants possessed loss of function effects on reconstituted I Ks -or I Kr -like channels. 3 The functional changes in mutant channels reconstituted by the computer simulation resulted in a mildly prolonged APD, suggesting that the dLQTS may partially have a genetic background, especially mild or latent long-QT syndromeassociated mutations.
Mutations in dLQTS
Potential torsadegenic drugs are used in the clinical setting and include antiarrhythmic drugs, antibiotics, antihistamines, psychiatric drugs, and cholinergic antagonists. These might induce TdP, which may lead to the sudden cardiac death of individuals whose QT intervals were within normal range before taking the drug. Several drugs such as cisapride and terfenadine have been withdrawn from the market because of these possible side effects. 25, 26 The incidence of dLQTS is not high, and the drugs lead to TdP in only a small percentage of individuals, suggesting that there may be an underlying genetic background that predisposes these individuals to the risk. In the medical literature, 13 KCNQ1 or KCNH2 mutations (13 of 15 mutations, 87%) associated with dLQTS, including 6 of the mutations identified in this present study, have been located in nonpore regions ( Figure 1B) . Mutations in nontransmembrane regions have been shown to cause either mild long-QT syndrome or benign clinical phenotypes. 27 Mutation sites may influence the clinical and basic electrophysiological characteristics of patients with dLQTS. It is of interest that Figure 6 . Simulation study of congenital and dLQTS-associated channels. A, Scheme showing a Markov model for I Kr channels and simulation results for voltage-clamp protocols with a modified the transition rate ␣i; ␣iϭ0.439ϫexp(Ϫ0.02352ϫ(V ϩ40))/K out . The 3 panels illustrate the result on the M756V/WT model, (a); the I-V relationship, (b); the I-V relationship for amplitudes of peak tail currents and (c); the steady-state inactivation curves. Open circles, WT; filled circles, mutant. B, Simulation study of action potential durations (APD). The parameters used for simulation were changed and matched the experimental results for voltage-clamp protocols. Myocardium models were stimulated at the cycle length of 600 ms for 5 minutes. C, Simulated APDs with I Kr -blocking effects. When I Kr conductance was decreased to 11% in each of the models, the D342V model showed early afterdepolarization, whereas the WT model had only slight prolonged APD. Bold lines, controls; dotted lines, models with I Kr -blocking effects.
the functional assay of our 7 mutations resulted in various levels of loss of function, but most of them showed no dominant negative suppression, which is usually observed in the classic cLQTS. Clinical characteristics during the drug intake were not significantly distinct from those of cLQTS, which shares a similar genetic background with the dLQTS. Several polymorphisms have been shown to be associated with dLQTS. 4, 28 Abbott et al 4 identified a polymorphism (T8A) of the KCNE2 gene encoding MiRP, a ␤-subunit for the I Kr channel, which is present in 1.6% of the population and is associated with TdP induced by quinidine or sulfamethoxazole/trimethoprim administration. Splawski et al 28 also found a heterozygous polymorphism involving substitution of serine with tyrosine (S1102Y) in the sodium channel gene SCN5A among blacks that increased the risk for drug-induced TdP. The polymorphism was present in 57% of 23 patients with proarrhythmic episodes but in only 13% of control subjects. These findings suggested that common genetic variations may increase the risk for development of drugrelated arrhythmias.
Roden et al 29 reported that cisapride could rescue trafficking of L1825P channel with a potentially sustained current and revealed a new mechanism of dLQTS with the Luo-Rudy model. However, in the genotyped subjects in the present study, dLQTS mainly resulted from the I Kr -blocking effect of culprit drugs in the presence of latent genetic backgrounds. Cardiac repolarization reserve may protect subjects against the drug-induced QT prolongation by I Kr -blocking drugs. 30, 31 In the presence of latent genetic backgrounds, however, reduction in the repolarization reserve unveils the presence of so-called "concealed" long-QT syndrome when drugs with I Kr -blocking effects are administered. The presence of borderline prolongation of the QT interval, together with personal information such as unexplained previous syncope and family history of premature sudden death, may help to prevent drug-induced arrhythmia even if a subject's Schwartz score is low, because they could have a potential risk of TdP. Special attention should be paid to family members of the index subject with drug-induced QT prolongation because Ϸ30% of family members were found to have a predisposing genetic background in the present study. Indeed, they may have inherited the risk for being susceptible to dLQTS.
Limitations of the Study
This study has some limitations. Bacause of the small cohort of dLQTS subjects, this study was not powered to quantify the overall prevalence of ion channel mutations in the group of subjects with drug-induced TdP; there was also a possible No burst mode ␣6ϭ10*e-6
No burst mode ␤6ϭ3*e-4 cLQTS SCN5A L1330P G Na ϭ16 G Na ϭ6.24
No burst mode ␣6ϭ10*e-6
No burst mode ␤6ϭ3*e-4 selection bias in the population. As for the causative agents, we were unable to test the action of amphetamine and methamphetamine because it was impossible to obtain these illegal drugs for clinical study. However, a previous report has shown that 3,4-methylenedioxy methamphetamine (ecstasy, NMDA) prolongs the APD of hippocampal neurons by blocking the conductance of a resting K ϩ channel. 32 It is quite possible that these drugs also suppressed cardiac K ϩ currents and induced QT prolongation and TdP in 1 subject in our study, based on her medical records. Regarding protein trafficking, 2 mutations in this study, A614V in KCNH2 17 and L1825P in SCN5A, 29 had been reported to be traffickingdeficient mutations. Though protein trafficking of other mutants remains unclear, especially R243H in KCNQ1, and H492Y, S706F, and M756V in KCNH2, would be not trafficking-deficient because, under heterozygous conditions, these mutants showed adequate current density compared with WT. In the simulation study, the parameter settings could mimic mutant channels. In addition, the setting of the parameters might have innumerable patterns, and it therefore remains possible that other combinations of patterns could also simulate mutant channels.
